BLRX BLRX
Company Profile ↓Company Overview
BLRX (BLRX) is a publicly traded company listed on with a market capitalization of $7.10B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $1.18M (-95.9% YoY); net profit $-1.18M.
- Trailing 12 Months Year-on-year growth — revenue -95.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -95.92% |
Stock Price Performance
| 1 Year: | -29.24% |
| 6 Months: | -10.62% |
| 3 Months: | -10.62% |
| 1 Month: | -14.02% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.61 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 38.8% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 255.00K | 304.00K | 427.00K | 194.00K | 477.00K |
| Cost of Revenue | - | 34.00K | 72.00K | 84.00K | 40.00K | 95.00K |
| Gross Profit | - | 221.00K | 232.00K | 343.00K | 154.00K | 382.00K |
| Operating Expenses | - | 2.61M | 2.54M | 2.55M | 3.54M | 3.39M |
| Operating Income | - | -2.39M | -2.30M | -2.21M | -3.39M | -3.00M |
| EBITDA | - | 5.71M | -3.49M | -554.00K | -1.92M | -2.25M |
| Interest Expense | - | 420.00K | 276.00K | 304.00K | 251.00K | 250.00K |
| Pretax Income | - | 5.13M | -3.94M | -977.00K | -2.24M | -2.59M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | 5.13M | -3.94M | -977.00K | -1.39M | -1.60M |
| Diluted EPS | - | 0.00 | 0.00 | 0.00 | - | 0.00 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 4.80M | 28.94M | 1.18M |
| Cost of Revenue | 0 | 3.69M | 9.26M | 230.00K |
| Gross Profit | 0 | 1.11M | 19.68M | 950.00K |
| Operating Expenses | 29.16M | 44.10M | 38.83M | 11.24M |
| Operating Income | -29.16M | -42.99M | -19.15M | -10.29M |
| EBITDA | -22.51M | -57.09M | 3.92M | -252.00K |
| Interest Expense | 1.79M | 2.14M | 9.07M | 1.25M |
| Pretax Income | -24.95M | -60.61M | -9.22M | -2.03M |
| Tax Provision | - | - | - | - |
| Net Income | -24.95M | -60.61M | -9.22M | -1.18M |
| Diluted EPS | -18.00 | -36.00 | -6.00 | 0.00 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 76.38M | 63.92M | 38.91M | 40.91M |
| Current Assets | - | 52.00M | 47.18M | 27.10M | 23.68M |
| Cash & Equivalents | - | 10.59M | 4.25M | 10.44M | 3.25M |
| Inventory | - | 0 | 1.95M | 3.15M | 2.15M |
| Receivables | - | 0 | 358.00K | 2.48M | 46.00K |
| Total Liabilities | - | 25.54M | 50.70M | 25.45M | 17.56M |
| Current Liabilities | - | 10.68M | 42.78M | 15.41M | 12.12M |
| Long Term Debt | - | 8.63M | 6.63M | 8.96M | 4.46M |
| Total Debt | - | 12.32M | 11.59M | 15.04M | 10.15M |
| Total Equity | - | 50.84M | 13.22M | 13.46M | 18.20M |
| Shares Outstanding | - | 922.96M | 1.09B | 1.34B | 2.61B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -26.24M | -22.61M | -43.87M | -8.07M |
| Investing Cash Flow | 4.01M | 1.44M | 29.37M | -8.54M |
| Financing Cash Flow | 20.44M | 15.06M | 20.66M | 8.88M |
| Capital Expenditure | -316.00K | -297.00K | -54.00K | -27.00K |
| Free Cash Flow | -26.56M | -22.91M | -43.93M | -8.10M |
| Net Change in Cash | -1.80M | -6.11M | 6.16M | -7.74M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | 23.1% | 68.0% | 80.5% |
| Operating Margin % | - | -895.6% | -66.2% | -871.8% |
| Net Margin % | - | -1,262.8% | -31.9% | -99.6% |
| ROE % | -49.1% | -458.4% | -68.5% | -6.5% |
| ROCE % | -44.4% | -203.4% | -81.5% | -35.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BLRX
Price to sales forward of BioLineRX Ltd. – TASE:BLRX - TradingView
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQTVp6bUhKREV3NzhvQnZIQ0VDaHdVVkdkWjI0Ti1FdnhEVzA1SEFkOThHd21TSUVJdF81Z1h0Zm90ZV9aaHJsWEV1cU9aMmE2ZnhwRHdVTkRETWFQbURpOHhRNkpFS2tIZzZFbVljb1JMUndTRm5iQ1pLU2lFMVdWaEY0NGN6OUoybFNHQU…
Preclinical Ovarian Cancer Data Show GLIX1-PARP Synergy - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNRnRnYzRwVnluZDdyUFp1SzhncVVBNUdHa1F2bVltYXhoQmJPLWhxWGFxYkx1SUdCajg5ZnhHUVZzTGc5TU9rM0JCNkJXbkJXTmJDT3g5N3ZrMmVnemUwdklMV1pYT3VkS25TMnlNRXVKYnp4eWZjdjEzWjl6YVl3cFd5NTUtUG9aYW9ZcV…
BLRX Stock Surges Pre-Market On Cancer Trial Catalyst – Eyes 50-DMA Breakout For First Time In Nearly 2 Months - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxOX3g1M1ZqSXRabWc0djFXR3A0V01IQ2lNTzBiWldZdEFtU2tDRUF2b3V5NnVCT0ZLalJiWlhIeTV0OFZoTFJzY1U0dUlTT0YzQU1DV0k0TGJ2UHlEd3F5TFNXVWpKYTY0SUpmaTZvcURrdU4tUWJiSjg5djZQVk00ekluRnVsdTByc0dMb2…
BioLineRx Shares Advance After First Patient Enrolled in GLIX1 Cancer Study (BLRX) - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOTXlwc0Q2d3dta2toNWZDTnZPNUhxWnctSHktaVlqTDU0NElBTTZ5U2VVa3kzUlotcUF5dDJOaG9WdFFZdEZOOUJrRGlwSGdQRW9sRFpwbXdVdjdmYlN1dnlHamk3SVpmRlhxenVkclNrc2pnbHlZTUtXSFR2RnE5MlY4THo1ZkpIMEZRYm…
BLRX|BioLine RX Ltd|Price:2.820|Chg%:+0.100 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9aSjFLVFlJemtVX1lDcTJuSjE4em5kano1R2Y5UkRLTTMyc2Y4OTNvRDdKZzFyeUlfMHlkbEZXSzF1Mll1NDJYNjAwOXRFMlZ6Si1qaEt6bHB0UTB2T0tua0FtaS1LbjkyU01VQTJB?oc=5" target="_blank">BLRX|BioLine RX Ltd…
BioLineRX Ltd. Revenue Breakdown – TASE:BLRX - TradingView
<a href="https://news.google.com/rss/articles/CBMidEFVX3lxTE5aNzZNeU0waXNia3V3V3RRYUpxaXFMa1RvejZ1R0h2ZExZRFRIT3ZVdGdnMmlqLU1JMWdINFdybW9FUjZ6d1VLRG1vZkI3OHZyR3VqMEtUeEJlM1Q2M3lrdVJTYVV1YVRJMmg3MTg0UjlQVkZQ?oc=5" target="_blank">BioLineRX L…
BLRX — Frequently Asked Questions
What is the current share price of BLRX?
As of 2026-08-05 17:25 PDT, BLRX trades at $2.72 on NASDAQ/NYSE. Its 52-week range is $2.18 to $4.44.
What is the market capitalisation of BLRX?
BLRX has a market capitalisation of $7.10B on NASDAQ/NYSE.
What is the return on equity (ROE) of BLRX?
BLRX has a return on equity (ROE) of -6.46%. Its return on capital employed (ROCE) is -35.74%.
Is BLRX a good stock to buy?
This page provides a data-driven analysis of BLRX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.